{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:50:57Z","timestamp":1762098657159,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s15010-020-01550-0","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T09:10:17Z","timestamp":1606036217000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Renin\u2013angiotensin system inhibitors and mortality in patients with COVID-19"],"prefix":"10.1007","volume":"49","author":[{"given":"Luca","family":"Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9119-4311","authenticated-orcid":false,"given":"Alessandro","family":"Malagoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Biagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Zanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Sticozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greta","family":"Comastri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Pannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Gandolfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Vergara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni Quinto","family":"Villani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"1550_CR1","unstructured":"WHO. Novel coronavirus\u2014China. Jan 12, 2020. 2020; https:\/\/www.who.int\/csr\/don\/12-january-2020-novel-coronavirus-china\/en\/. Accessed 15 April 2020."},{"key":"1550_CR2","unstructured":"WHO. Director-General's opening remarks at the media briefing on COVID-19: 11 March 2020. Published March 11, 2020. 2020; https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020. Accessed 16 April 2020."},{"key":"1550_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497\u2013506.","journal-title":"Lancet"},{"key":"1550_CR4","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061\u20139.","journal-title":"JAMA"},{"key":"1550_CR5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrier T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271\u201380.","journal-title":"Cell"},{"key":"1550_CR6","unstructured":"WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. January 28, 2020. 2020. Accessed 5 March 2020."},{"key":"1550_CR7","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. J Hypertens. 2018;36:1953\u20132041.","journal-title":"J Hypertens"},{"key":"1550_CR8","unstructured":"National Health Commission of the People\u2019s Republic of China Diagnosis and treatment protocol for COVID-19 (trial version 7) 2020. https:\/\/www.chinadaily.com.cn\/pdf\/2020\/1.Clinical.Protocols.for.the.Diagnosis.and.Treatment.of.COVID-19.V7.pdf."},{"key":"1550_CR9","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708\u201320.","journal-title":"N Engl J Med"},{"key":"1550_CR10","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0140-6736(17)32478-9","volume":"390","author":"J Lu","year":"2017","unstructured":"Lu J, Lu Y, Wang X, Li X, Linderman GC, Wu C, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet. 2017;390:2549\u201358.","journal-title":"Lancet"},{"key":"1550_CR11","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","volume":"71","author":"FH Messerli","year":"2018","unstructured":"Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol. 2018;71:1474\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"1550_CR12","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/heartjnl-2016-310705","volume":"103","author":"L Potier","year":"2017","unstructured":"Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart. 2017;103:1339\u201346.","journal-title":"Heart"},{"key":"1550_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13054-017-1823-x","volume":"21","author":"A Khan","year":"2017","unstructured":"Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Crit Care. 2017;21:234.","journal-title":"Crit Care"},{"key":"1550_CR14","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","volume":"43","author":"Y Ishiyama","year":"2004","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43:970\u20136.","journal-title":"Hypertension"},{"key":"1550_CR15","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00134-020-05985-9","volume":"46","author":"H Zhang","year":"2020","unstructured":"Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586\u201390.","journal-title":"Intensive Care Med"},{"key":"1550_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875\u20139.","journal-title":"Nat Med"},{"key":"1550_CR17","doi-asserted-by":"publisher","first-page":"e016509","DOI":"10.1161\/JAHA.120.016509","volume":"9","author":"R Sommerstein","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, Grani C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9:e016509.","journal-title":"J Am Heart Assoc"},{"key":"1550_CR18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381.","journal-title":"Circ Res"},{"key":"1550_CR19","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1164\/rccm.202002-0445OC","volume":"201","author":"Y Feng","year":"2020","unstructured":"Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: a multi-center study of clinical features. Am J Respir Crit Care Med. 2020;201:1380\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1550_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ahj.2020.05.002","volume":"226","author":"RD Lopes","year":"2020","unstructured":"Lopes RD, Macedo AV, Melo de Barros e Silva PG, JunqueiraMoll-Bernardes R, Feldman A, SabaArruda GD, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)\u2014The BRACE CORONA Trial. Am Heart J. 2020;226:49\u201359.","journal-title":"Am Heart J."},{"key":"1550_CR21","unstructured":"ClinicalTrials.gov. Coronavirus (COVID-19) ACEi\/ARB investigation (CORONACION). ClinicalTrials.gov identifier: NCT04330300. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04330300. Accessed 10 June 2020."},{"key":"1550_CR22","unstructured":"ClinicalTrials.gov. ACE inhibitors or ARBs discontinuation in context of SARS-CoV-2 pandemic (ACORES-2). ClinicalTrials.gov identifier: NCT04329195. https:\/\/clinicaltrials.gov\/ct2\/show\/. Accessed 10 June 2020."},{"key":"1550_CR23","unstructured":"ClinicalTrials.gov. Losartan for patients with COVID-19 not requiring hospitalization. ClinicalTrials.gov identifier: NCT04311177. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311177. Accessed 10 June 2020."}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01550-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-020-01550-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-020-01550-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T09:27:53Z","timestamp":1616578073000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-020-01550-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1550"],"URL":"https:\/\/doi.org\/10.1007\/s15010-020-01550-0","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"type":"print","value":"0300-8126"},{"type":"electronic","value":"1439-0973"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}